High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer

doi:10.3748/wjg.v32.i8.115333

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 8

This Article

(40)

(77)

(0)

(14)

(869)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Feb 28, 2026; 32(8): 115333
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.115333

Table 2 Clinicopathological features associated with high programmed death ligand-1 expression group in pathological stage III gastric or gastroesophageal junction cancer

Variables	High PD-L1 expression (n = 116)	Low PD-L1 expression (n = 113)	Statistic	P value
Sex			1.914	0.167
Male	78 (67.2)	66 (58.4)
Female	38 (32.8)	47 (41.6)
Age (year)	59.51 ± 12.05	55.41 ± 13.31	-2.445	0.015
Tumor size (cm)			0.002	0.964
< 5	76 (66.1)	75 (66.4)
≥ 5	39 (33.9)	38 (33.6)
Lesion sites			3.194	0.074
Stomach	79 (69.3)	90 (79.6)
GEJ	35 (30.7)	23 (20.4)
Histology			4.007	0.045
Sig	40 (35.1)	54 (48.2)
Others	74 (64.9)	58 (51.8)
Grade			0.888	0.346
G1-G2	19 (17.0)	14 (12.5)
G3	93 (83.0)	98 (87.5)
Pathological stage			1.263	0.532
pIIIA	51 (44.0)	48 (42.5)
pIIIB	39 (33.6)	45 (39.8)
pIIIC	26 (22.4)	20 (17.7)
HER-2 expression			0.728	0.394
Negative	100 (89.3)	100 (92.6)
Positive	12 (10.7)	8 (7.4)
MMR status			0.000	1.000
dMMR	5 (4.3)	4 (3.5)
pMMR	111 (95.7)	109 (96.5)
EBV status			1.779	0.182
Negative	105 (93.8)	108 (98.2)
Positive	7 (6.3)	2 (1.8)
Ki-67 index	63.78 ± 22.09	55.36 ± 23.28	-2.795	0.006
Postoperative adjuvant chemotherapy			0.929	0.335
Yes	72 (62.1)	77 (68.1)
No	44 (37.9)	36 (31.9)

Data were shown as n (%) or mean ± SD. GEJ: Gastroesophageal junction; Sig: Signet ring cell carcinoma; pIII: Pathological stage III; MMR: Mismatch repair; dMMR: Deficient mismatch repair; pMMR: Proficient mismatch repair; EBV: Epstein-Barr virus; PD-L1: Programmed death ligand-1.

Full Size Table

Citation: Zhang HM, Li FP, Zhang HY, Liu XR, Chen XH, Liang HY, Yan X, Xie Q, Zhong R, Lai M, Zhong XF, Liu H, Zhao LY. High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer. World J Gastroenterol 2026; 32(8): 115333
URL: https://www.wjgnet.com/1007-9327/full/v32/i8/115333.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i8.115333

Zhang HM, Li FP, Zhang HY, Liu XR, Chen XH, Liang HY, Yan X, Xie Q, Zhong R, Lai M, Zhong XF, Liu H, Zhao LY. High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer. World J Gastroenterol 2026; 32(8): 115333 [PMID: 41809879 DOI: 10.3748/wjg.v32.i8.115333]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.